Get started
Author

Elizabeth Panora

Observed name: E. Panora
ORCID: 0000-0003-1076-8032
Observed ORCID: 0000-0003-1076-8032
OpenAlex ID: A5042150737
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2018 · Fernando C. Santini, Hira Rizvi, et al. · Cancer Immunology Research · 331
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
2018 · Bob T. Li, Vicky Makker, et al. · Journal of Clinical Oncology · 52
Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy.
2017 · Fernando Costa Santini, Hira Rizvi, et al. · Journal of Clinical Oncology · 52
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
2019 · Alexander Drilon, Adam J. Schoenfeld, et al. · Molecular Case Studies · 31
PDF
Mentoring Hispanic Undergraduate and Graduate Research Assistants: Building Research Capacity in Nursing
2015 · Judith Aponte, Brenda N. Figueroa, et al. · Journal of Nursing Education · 12
89Zr-Trastuzumab PET/CT for Prediction of Response to HER2-targeted therapy in Patients with HER2 Mutant Lung Cancer: An Exploratory Phase 2 Trial
2019 · Gary A. Ulaner, Michael Offin, et al. · Journal of Nuclear Medicine · 5
P1.13-43 Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial
2018 · B. Li, M. Offin, et al. · Journal of Thoracic Oncology · 5
Data from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Table 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Table 3 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Figure 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Figure 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Table 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Table 3 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Figure 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Table 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Figure 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Supplemental Table 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Data from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
2023 · Fernando C. Santini, Hira Rizvi, et al.
Works count: 19
Citation count: 488
H-index: 5
I10-index: 5
Year
Topic
Type